2. Search Result
Search Result
Results for "

Kinase selectivity

" in MedChemExpress (MCE) Product Catalog:

1421

Inhibitors & Agonists

9

Screening Libraries

4

Fluorescent Dye

5

Biochemical Assay Reagents

30

Peptides

1

Inhibitory Antibodies

32

Natural
Products

38

Isotope-Labeled Compounds

12

Click Chemistry

1

Oligonucleotides

4

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15979
    H-89
    175+ Cited Publications

    		 PKA Autophagy Neurological Disease
    H-89 is a potent and selective inhibitor of cyclic AMP-dependent protein kinase (protein kinase A) with IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase, and others kinases.
    H-89
  • HY-15979A
    H-89 dihydrochloride
    175+ Cited Publications

    		 PKA Autophagy Others
    H-89 dihydrochloride is a potent and selective inhibitor of protein kinase A (PKA) with an IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase.
    H-89 dihydrochloride
  • HY-10578
    PD 169316
    25+ Cited Publications

    		 p38 MAPK Autophagy Enterovirus Cancer
    PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor, with IC50 of 89 nM. PD169316 selectively inhibits the kinase activity of the phosphorylated p38 without hindering upstream kinases to phosphorylate p38. PD169316 shows antiviral activity against Enterovirus71. PD169316 shows antiviral activity against Enterovirus71.
    PD 169316
  • HY-13820
    GSK2656157
    60+ Cited Publications

    		 PERK Autophagy Apoptosis Cancer
    GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) with an IC50 of 0.9 nM.
    GSK2656157
  • HY-111941
    GSK8612
    25+ Cited Publications

    		 IKK Neurological Disease Inflammation/Immunology Cancer
    GSK8612 is a highly selective and potent Tank-binding Kinase-1 (TBK1) inhibitor, with a pIC50 of 6.8 for recombinant TBK1 .
    GSK8612
  • HY-10917
    GW2580
    10+ Cited Publications

    		 c-Fms Inflammation/Immunology Cancer
    GW2580 is an orally bioavailable and selective inhibitor of c-Fms kinase which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling .
    GW2580
  • HY-15604
    AZD1208
    20+ Cited Publications

    		 Pim Autophagy Apoptosis Cancer
    AZD1208 is an orally bioavailable, highly selective PIM kinases inhibitor .
    AZD1208
  • HY-10180
    MLN8054
    5+ Cited Publications

    		 Aurora Kinase Cancer
    MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC50 of 4 nM.
    MLN8054
  • HY-59090
    1-Azakenpaullone
    3 Publications Verification

    1-Akp

    		 GSK-3 Neurological Disease Metabolic Disease
    1-Azakenpaullone (1-Akp) is a highly selective and ATP-competitive inhibitor of glycogen synthase kinase-3 β (GSK-3β), with an IC50 value of 18 nM .
    1-Azakenpaullone
  • HY-16956
    Onatasertib
    3 Publications Verification

    CC-223; ATG-008

    		 mTOR Apoptosis Cancer
    Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. Onatasertib inhibits both mTORC1 and mTORC2.
    Onatasertib
  • HY-101296
    PD-166866
    10+ Cited Publications

    		 FGFR Autophagy Cancer
    PD166866 is a selective FGFR1 tyrosine kinase inhibitor with an IC50 of 52.4 nM.
    PD-166866
  • HY-13946
    BML-277
    5+ Cited Publications

    Chk2 Inhibitor II

    		 Checkpoint Kinase (Chk) Apoptosis Cancer
    BML-277 is a selective checkpoint kinase 2 (Chk2) inhibitor with an IC50 of 15 nM.
    BML-277
  • HY-50686
    Tivantinib
    5+ Cited Publications

    ARQ 197; (3R,4R)-ARQ 198

    		 c-Met/HGFR Apoptosis Cancer
    Tivantinib is a highly selective c-Met tyrosine kinase inhibitor with a Ki of 355 nM.
    Tivantinib
  • HY-W011109
    CKI-7
    1 Publications Verification

    		 Casein Kinase CDK SGK Ribosomal S6 Kinase (RSK) Cancer
    CKI-7 is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 is a selective Cdc7 kinase inhibitor. CKI-7 also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 has a much weaker effect on casein kinase II and other protein kinases .
    CKI-7
  • HY-15300
    Skepinone-L
    2 Publications Verification

    CBS3830

    		 p38 MAPK Autophagy Inflammation/Immunology
    Skepinone-L (CBS3830), a chemical probe, is a selective p38 mitogen-activated protein kinase inhibitor.
    Skepinone-L
  • HY-12948
    AMG319
    1 Publications Verification

    		 PI3K Cancer
    AMG319 is a potent and selective PI3Kδ kinase inhibitor with IC50 of 18 nM.
    AMG319
  • HY-12401
    Mps1-IN-3
    1 Publications Verification

    		 Mps1 Cancer
    Mps1-IN-3 is a potent and selective MPS1 kinase inhibitor, with an IC50 of 50 nM.
    Mps1-IN-3
  • HY-148794
    Risvodetinib

    IkT-148009

    		 c-Met/HGFR Bcr-Abl Neurological Disease Cancer
    Risvodetinib (IkT-148009) is an orally active, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying excellent target efficacy against c-Abl1, c-Abl2/Arg with IC50 values of 33 nM, 14 nM, respectively. Risvodetinib suppresses c-Abl activation and substantially protects dopaminergic neurons from degeneration in mouse models of both inherited and sporadic Parkinson’s disease (PD), which is promising for research in the field of PD .
    Risvodetinib
  • HY-152155
    ARUK2001607

    		PI5P4K Inflammation/Immunology Cancer
    ARUK2001607 is a selective phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) inhibitor with a Kd of 7.1 nM. ARUK2001607 shows high selectivity over other >150 kinases .
    ARUK2001607
  • HY-100556
    Tie2 kinase inhibitor 1
    1 Publications Verification

    		 Tie Cancer
    Tie2 kinase inhibitor 1 (compound 5) is a potent, selective Tie2 kinase inhibitor with an IC50 of 250 nM . Tie2 kinase inhibitor 1 has anti-cancer activity .
    Tie2 kinase inhibitor 1
  • HY-59047
    Tolimidone
    4 Publications Verification

    MLR-1023

    		 Src Metabolic Disease
    Tolimidone is a potent and selective allosteric activator of Lyn kinase with an EC50 of 63 nM.
    Tolimidone
  • HY-101525
    MBP146-78
    3 Publications Verification

    		 Parasite Infection
    MBP146-78 is a potent and selective inhibitor of cGMP dependent protein kinases.
    MBP146-78
  • HY-112136
    TAO Kinase inhibitor 1
    5+ Cited Publications

    CP 43

    		 MAP3K Mitosis Cancer
    TAO Kinase inhibitor 1 (compound 43) is a selective, ATP-competitive thousand-and-one amino acid kinases (TAOK) inhibitor with IC50s of 11 to 15 nM for TAOK1 and 2, respectively. TAO Kinase inhibitor 1 delays mitosis and induces mitotic cell death .
    TAO Kinase inhibitor 1
  • HY-129571
    BioE-1115

    		PASK/STK37 Ser/Thr Protease Casein Kinase Metabolic Disease
    BioE-1115 is a highly selective and potent PAS kinase (PASK) inhibitor with an IC50 of ~4 nM. BioE-1115 is also a potent casein kinase 2α inhibitor with an IC50 of ~10 μM .
    BioE-1115
  • HY-109143
    Elsubrutinib
    2 Publications Verification

    ABBV-105

    		 Btk Inflammation/Immunology
    Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine kinase (BTK) inhibitor. The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease .
    Elsubrutinib
  • HY-46531
    Thalidomide-5-NH2-CH2-COOH

    		E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis Inflammation/Immunology Cancer
    Thalidomide-5-NH2-CH2-COOH (compound 114) is a potent and selective inhibitor of tropomyosin receptor kinase (trk). Thalidomide-5-NH2-CH2-COOH is a ligand of E3 ligase. Thalidomide-5-NH2-CH2-COOH has the potential for researching one or more diseases (extracted from patent WO2021170109A1) .
    Thalidomide-5-NH2-CH2-COOH
  • HY-15951
    ML167

    CID44968231; NCGC00188654

    		 CDK DYRK Cancer
    ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor with IC50 of 136 nM, >10-fold selectivity for closely related kinases Clk1, Clk2, Clk3 and Dyrk1A/1B .
    ML167
  • HY-B0788A
    LY2409881 trihydrochloride
    4 Publications Verification

    		 IKK Apoptosis Cancer
    LY2409881 trihydrochloride is a selective IκB kinase β (IKK2) inhibitor with an IC50 of 30 nM.
    LY2409881 trihydrochloride
  • HY-107988
    MK-3903
    3 Publications Verification

    		 AMPK Metabolic Disease
    MK-3903 is a potent and selective AMP-activated protein kinase (AMPK) activator with an EC50 of 8 nM.
    MK-3903
  • HY-110052
    TBCA
    1 Publications Verification

    		 Casein Kinase Cancer
    TBCA is a highly selective CK2 (casein kinase II) inhibitor with an IC50 of 110 nM and a Ki of 77 nM. TBCA shows selectivity for CK2 over CK1, DYRK1A and a panel of 27 other kinases .
    TBCA
  • HY-19362
    AZD3264
    2 Publications Verification

    		 IKK Inflammation/Immunology
    AZD3264 is a selective IkB-kinase IKK2 inhibitor.
    AZD3264
  • HY-19353
    SR7826
    1 Publications Verification

    		 LIM Kinase (LIMK) Neurological Disease Cancer
    SR7826 is a class of bis-aryl urea derived potent, selective and orally active LIM kinase (LIMK) inhibitor with an IC50 of 43 nM for LIMK1. SR7826 is >100-fold more selective for LIMK1 than ROCK and JNK kinases .
    SR7826
  • HY-152107
    LRRK2-IN-7

    		LRRK2 Neurological Disease
    LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes .
    LRRK2-IN-7
  • HY-12787
    L-779450
    1 Publications Verification

    		 Raf Autophagy Cancer
    L-779450 is a potent and selective B-Raf kinase inhibitor with a Kd of 2.4 nM.
    L-779450
  • HY-111507
    PDGFRα kinase inhibitor 1
    1 Publications Verification

    		 PDGFR Cancer
    PDGFRα kinase inhibitor 1 is a highly selective type II PDGFRα kinase inhibitor with IC50s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively .
    PDGFRα kinase inhibitor 1
  • HY-D2415
    BODIPY-FL staurosporine

    		Fluorescent Dye Others
    BODIPY-FL staurosporine (Compound 8a) is a fluorescence probe based on staurosporine, exhibiting high specificity towards tyrosine kinases (TK) and tyrosine kinase-like (TKL) family kinases. BODIPY-FL staurosporine has the potential to develop binding assays for kinases that are not recommended for use with Kinase Tracer 236, such as PIM3, CDC42BPG, MAP2K7, TXK, and SIK3. BODIPY-FL staurosporine can be a powerful tool for analyzing kinase selectivity in kinase drug discovery .
    BODIPY-FL staurosporine
  • HY-137813
    PERK-IN-4

    		PERK Neurological Disease Metabolic Disease Cancer
    PERK-IN-4 is a potent and selective PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase) inhibitor with an IC 50 of 0.3 nM. PERK is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states .
    PERK-IN-4
  • HY-132293
    BAY-8400
    3 Publications Verification

    		 DNA-PK Cancer
    BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (IC50=81 nM). BAY-8400 can be used for the research of cancer .
    BAY-8400
  • HY-126323
    TCMDC-135051

    		Parasite Infection
    TCMDC-135051 is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 has antiparasiticidal activity (EC50=320 nM) .
    TCMDC-135051
  • HY-128601
    CHK1-IN-3

    		Checkpoint Kinase (Chk) Cardiovascular Disease Cancer
    CHK1-IN-3 is a potent and selective CHK1 inhibitor with an IC50 of 0.4 nM. CHK1-IN-3 effectively inhibits the growth of malignant hematopathy cell lines and displays low affinity for hERG (IC50 > 40 μM). CHK1-IN-3 significantly suppresses the tumor growth in vivo. CHK1-IN-3 can be used for the study of hematologic malignancies .
    CHK1-IN-3
  • HY-112355
    Aurora kinase inhibitor-2

    		Aurora Kinase Cancer
    Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively .
    Aurora kinase inhibitor-2
  • HY-150640
    Rho-Kinase-IN-2

    		ROCK Neurological Disease Inflammation/Immunology Cancer
    Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and CNS-penetrant Rho Kinase (ROCK) inhibitor (ROCK2 IC50 = 3 nM). Rho-Kinase-IN-2 can be used in Huntington’s research .
    Rho-Kinase-IN-2
  • HY-15159
    Cyclapolin 9

    		Polo-like Kinase (PLK) Cancer
    Cyclapolin 9 is a potent, selective and ATP-competitive polo-like kinase 1 (PLK1) inhibitor with an IC50 of 500 nM. Cyclapolin 9 is inactive against other kinases .
    Cyclapolin 9
  • HY-157767
    Abd110

    		PROTACs ATM/ATR Cancer
    Abd110 (compound 42i) is a Lenalidomide-based PROTAC ATR kinase degrader. Abd110 selectively decreases ATR and phospho-ATR without affecting related kinases ATM and DNA-PKcs .
    Abd110
  • HY-164756
    PKCTheta-IN-2

    		PKC Inflammation/Immunology
    PKCTheta-IN-2 (compound 14) is a potent and selective PKCθ inhibitor with an IC50 of 0.25 nM. PKCTheta-IN-2 shows good selectivity over a wide range of kinases, including the PKC subfamily (30 kinases). PKCTheta-IN-2 inhibits the IL-2 production in a mouse (IC50 of 682 nM) .
    PKCTheta-IN-2
  • HY-112373
    Aurora kinase inhibitor-3

    		Aurora Kinase Others
    Aurora kinase inhibitor-3 is a strong and selective Aurora A kinase inhibitor with an IC50 of 42 nM, and weakly inhibits EGFR with an IC50 of >10 μM. Aurora kinase inhibitor-3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket .
    Aurora kinase inhibitor-3
  • HY-131335
    p38α inhibitor 2

    		p38 MAPK Inflammation/Immunology
    p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC50 of 9.6. p38α inhibitor 2 inhibits the hERG ion channel (IC50=27 μM) and shows a promising selectivity profile when tested in a panel of 51 other protein kinases (<30% inhibition at 10 μM concentration) and a panel of 141 other biological targets .
    p38α inhibitor 2
  • HY-163476
    PIP5K1C-IN-1

    		PI4P5K Inflammation/Immunology Cancer
    PIP5K1C-IN-1 (Compound 30) is a potent PIP5K1C inhibitor, with an IC50 of 0.80 nM. PIP5K1C-IN-1 exhibits low total clearance in mice and high levels of kinase selectivity. PIP5K1C-IN-1 can be used for the research of cancer and chronic pain .
    PIP5K1C-IN-1
  • HY-117393
    Bisindolylmaleimide III
    1 Publications Verification

    		 PKC Cancer
    Bisindolylmaleimide III is a potent and selective inhibitor of protein kinase C (PKC). Bisindolylmaleimide III selectively interacts with either PKCα or ribosomal S6 protein kinase 1 after activation of these kinases .
    Bisindolylmaleimide III
  • HY-18227
    B-Raf IN 1

    		Raf Cancer
    B-Raf IN 1 is a potent and selective B-Raf kinase inhibitor with an IC50 of 24 nM.
    B-Raf IN 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: